logo-loader

AXIM Biotechnologies kicks of human clinical trial for eczema ointment

Last updated: 10:07 17 May 2016 EDT, First published: 05:07 17 May 2016 EDT

Pictured is a person's back under a magnifying glass
Conducting the clinical trials is a specialist on psoriasis and atopic dermatitis, Dr. Marcus Meinardi, at The Maurits Clinics in The Hague, The Netherlands, the firm said.

AXIM Biotechnologies Inc (OTC:AXIM), which has a market cap of US$17mln, has started human clinical trials for its ointment AX-1602 for psoriasis and eczema.

The candidate includes the “stem cell cannabinoid” cannabigerol (CBG) and other cannabinoids.

Together, these two conditions will affect nearly 200mln people worldwide by 2024 and combined market estimates are $16 billion by 2022, the firm pointed out.

Conducting the clinical trials is  a specialist on psoriasis and atopic dermatitis, Dr. Marcus Meinardi, at The Maurits Clinics in The Hague, The Netherlands, the firm said.

AXIM’s chief executive Dr George Anastassov, said: “We are extremely pleased that our ongoing efforts in finding solutions to conditions for which there are no effective treatments or the ones available are associated with significant side effects (e.g. immunosuppression) are culminating with the clinical trials of our Renecann product. 

"Psoriasis and atopic dermatitis are debilitating conditions causing significant decrease in quality of life.  Utilising our proprietary technologies and incorporating unique cannabinoids, we believe that we will be able to effectively address these concerns."

Lekhram Changoer, the group's chief technology officer, added: "Following the successful completion of this clinical trial, AXIM products will be registered as an ointment for various skin disorders.”

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

2 hours, 52 minutes ago